Back to results
US 2019/0336461 A1Published application
Pharmaceutical composition for controlled release of treprostinil
AssigneesPharmosa Biopharm Inc., Pharmosa Therapeutics, Inc.
InventorsPei KAN, Yi Fong LIN, Ko Chieh CHEN
Life of this patent
Estimating the term…
Abstract
Provided herein are pharmaceutical compositions containing (a) at least one liposome includes at least one vesicle-forming phospholipid; and (b) treprostinil encapsulated within the liposome. The ratio of treprostinil to phospholipid is equal to or higher than 0.035 and provides a controlled release of treprostinil. Also provided is the use of the pharmaceutical compositions to treat respiratory diseases.
Claims24
A pharmaceutical composition, comprising:
- one or more liposome suspended in an external medium, said liposome comprising:
- (a) an external lipid bilayer, comprising at least one vesicle-forming phospholipid;
- and
- (b) an internal aqueous medium, comprising treprostinil and a salt to provide a pH gradient between the internal aqueous medium and the external medium,
- wherein the weight ratio of treprostinil to the at least one vesicle-forming phospholipid (i.e., T/P ratio) is equal to or higher than about 0.035 and about less than 60% of the treprostinil is released within 2 hours after the administration of the pharmaceutical composition and more than 80% of the treprostinil is released more than 2 hours to about 72 hours after the administration of the pharmaceutical composition.
2 more elements
A method of treating a respiratory disease, comprising the steps of administering a pharmaceutical composition comprising:
- one or more liposome, said liposome comprising:
- (a) an external lipid bilayer, comprising at least one vesicle-forming phospholipid;
- and
- (b) an internal aqueous medium, comprising treprostinil and a salt to provide a pH gradient between the internal aqueous medium,
- wherein the weight ratio of treprostinil to the at least one vesicle-forming phospholipid (i.e., T/P ratio) is equal to or higher than about 0.035 and about less than 60% of the treprostinil is released within 2 hours after the administration of the pharmaceutical composition and more than 80% of the treprostinil is released more than 2 hours to about 72 hours after the administration of the pharmaceutical composition.
2 more elements
Dependencies are inferred from the claim text.